Philip Morris International's subsidiary in Indonesia, Sampoerna, held a ribbon-cutting ceremony on January 12 in Karawang City, West Java for a factory that produces IQOS HEETSpod. The factory, which began construction in the fourth quarter of 2022 and has an investment of over $186 million, will serve customers in Indonesia and the Asia-Pacific region and aligns with the government's policies to encourage investment and increase finished product exports. Minister of Economic Affairs Coordination, Airlangga Hartarto, said during the opening ceremony that the investment will stimulate innovation and create value in other sectors, such as retail, agriculture, and research and development. PMI reports that the Indonesian factory is its seventh innovation factory for smokeless products worldwide and its first in Southeast Asia. Sampoerna CEO Vassilis Gkatzelis expressed gratitude to the Indonesian government for creating a favorable investment environment and for its commitment to maintaining economic stability. He also noted PMI's significant investment in smoking alternatives, with over $9 billion invested in developing, scientific research, and commercializing smoke-free tobacco products. IQOS first appeared in limited market tests in Indonesia in 2019 and has been listed in cities such as Jakarta, Surabaya, Denpasar, and Bandung.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
